



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/019,258	09/23/2002	Preben Lexow	1181-256	1289
6449	7590	07/13/2007	EXAMINER	
ROTHWELL, FIGG, ERNST & MANBECK, P.C.			WHISENANT, ETHAN C	
1425 K STREET, N.W.				
SUITE 800			ART UNIT	PAPER NUMBER
WASHINGTON, DC 20005			1634	
			NOTIFICATION DATE	DELIVERY MODE
			07/13/2007	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PTO-PAT-Email@rfem.com

Office Action Summary	Application No.	Applicant(s)
	10/019,258	LEXOW, PREBEN
	Examiner Ethan Whisenant, Ph.D.	Art Unit 1634

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 22 June 2007.
 2a) This action is **FINAL**. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 15,19,20 and 22-24 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) 15,19,20 and 22 is/are allowed.
 6) Claim(s) 23 and 24 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO/SB/08)
 Paper No(s)/Mail Date _____

4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date _____.
 5) Notice of Informal Patent Application
 6) Other: _____.

NON-FINAL ACTION

1. The applicant's Response to the Final Office Action has been received (22 JUN 07) and considered. The applicant's response has been entered. **The finality of the previous Office action has been withdrawn in order to make a new grounds of rejection.**

35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that may form the basis for rejections set forth in this Office action:

A person shall be entitled to a patent unless --

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

or

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

3. The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

35 USC § 103

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

5. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. § 103, the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligations under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of potential 35 U.S.C. § 102(f) or (g) prior art under 35 U.S.C. § 103.

CLAIM REJECTIONS UNDER 35 USC § 102/103

6. **Claim(s) 23** is/are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Rothstein et al. [Methods in Enzymology 68 :98-109 (1979)].

Claim 23 is drawn to a library comprising a plurality of double stranded nucleic acid fragments as defined in Claim 15 (i.e. double stranded nucleic acid fragments, each fragment consisting of 8 to 25 bases and each fragment comprising at least one single stranded region that is capable of hybridizing to at least one other fragment).

Rothstein et al. teach a library comprising a plurality of double stranded nucleic acid fragments each fragment consisting of 8 to 25 bases and each fragment comprising at least one single stranded region that is capable of hybridizing to at least one other fragment. See Figure 3 and note the section of part (a) which I have labeled

as I-III. Each of the double stranded fragments shown in Figure 3 consist of 20 bases (i.e. between 8 and 25 bases) and comprise a single stranded region capable of hybridizing to at least one other fragment. Admittedly, Rothstein et al. do not teach that the fragments comprise at least one sequence of between 4 to 10 bases that represent a unit of binary code however, this limitation is directed to the intended use of the fragments and therefore does not further limit the product being claimed in Claim 23.

CLAIM REJECTIONS UNDER 35 USC § 103

7. **Claim(s) 24** is/are rejected under 35 U.S.C. 103(a) as being unpatentable over Rothstein et al. [Methods in Enzymology 68 :98-109 (1979)] in view of the Stratagene Catalog [p.39 (1988)].

Claim 24 is drawn to a kit comprising a library of double stranded nucleic acid fragments as defined in Claim 15 (i.e. double stranded nucleic acid fragments, each fragment consisting of 8 to 25 bases and each fragment comprising at least one single stranded region that is capable of hybridizing to at least one other fragment), the kit also comprising a ligase.

Rothstein et al. teach a library comprising a plurality of double stranded nucleic acid fragments each fragment consisting of 8 to 25 bases and each fragment comprising at least one single stranded region that is capable of hybridizing to at least one other fragment. See Figure 3 and note the section of part (a) which I have drawn a rectangle around and labeled as I-III. Each of the double stranded fragments shown in Figure 3 consist of 20 bases (i.e. between 8 and 25 bases) and comprise a single stranded region capable of hybridizing to at least one other fragment. Admittedly, Rothstein et al. do not teach that the fragments comprise at least one sequence of between 4 to 10 bases that represent a unit of binary code however, this limitation is directed to the intended use of the fragments and therefore does not further limit the product being claimed in Claim 24. Rothstein et al. do teach using a ligase to practice

their method. Rothstein et al. do not teach a kit comprising the reagents necessary for carrying out their method. However, as evidenced by the Stratagene Catalog teaching, it was well known at the time of the invention to place the reagents needed to perform a nucleic acid based assay into a kit format. In addition the Stratagene catalog teaches the advantages of assembling a kit, such as, saving resources and reducing waste. Therefore, absent an unexpected result, it would have been *prima facie* obvious to the ordinary artisan at the time of the invention to modify the teachings of Rothstein et al. with the teachings of the Stratagene Catalog wherein the reagents necessary to perform the method taught by Rothstein et al. are placed into a kit format. The ordinary artisan would have been motivated to make this modification in order to take advantage of the savings and efficiency afforded by kits.

REASON FOR ALLOWANCE

8. Claim(s) 15, 19-20 and 22 is/are allowable for the reason(s) of record.

CONCLUSION

9. Claim(s) 15, 19-20 and 22 is/are allowable while Claim(s) 23 and 24 is/are rejected and/or objected to for the reason(s) set forth above.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ethan Whisenant, Ph.D. whose telephone number is (571) 272-0754. The examiner can normally be reached Monday-Friday from 8:30AM - 5:30PM EST or any time via voice mail. If repeated attempts to reach the examiner by

Art Unit: 1634

telephone are unsuccessful, the examiner's supervisor, Ram Shukla, can be reached at (571) 272-0735.

The Central Fax number for the USPTO is (571) 273-8300. Please note that the faxing of papers must conform with the Notice to Comply published in the Official Gazette, 1096 OG 30 (November 15, 1989).



**ETHAN WHISENANT
PRIMARY EXAMINER**

Art Unit 1634